Topotarget (CPH: TOPO) has now recovered much of the ground it lost following confusing cancer of unknown primary trial results released earlier this year, that had put not only the said indication but the entire solid tumour field use of the compound in question. The stock market price recovery follows further streamlining of the business and even a change at the helm with CEO Martelet leaving the company shortly after CUP data. Topotarget then hired ABG Sundal Collier to assist in exploring next steps for the company should take. Those could include sale, merger, a new ex-US partner or other capital injection.
Then just weeks after that it released information that the most important short-term catalyst, a pivotal trial in Peripheral T-Cell Lymphoma or PTCL was going to meet its primary endpoint. Topotarget’s partner Spectrum Pharmaceuticals (NASDAQ: SPPI) distanced itself from jumping into such conclusion, merely saying that a few patients continue on the study and it is satisfied with initial analysis of the data and replied journalists saying it is more conservative in its communications than Topotarget. There has been much speculation on why the two firms did not seem to be completely on the same page in this matter, but it does not necessarily have to mean there is any red herring on the table.
Today the Danish company released information saying that belinostat in combination with doxorubicin in soft tissue sarcoma met predefined protocol criteria to continue into further clinical development. The open-label non-randomized, multicenter, phase I/II trial was started to assess the efficacy and safety of the compound with dose level and toxicity and efficacy as primary and response and survival endpoints as secondary outcome measures
No comments:
Post a Comment